SCHEMBL23945916

SCHEMBL23945916

C[C@H](CCc1cccc2c1n(C)c(=O)n2C1CCC(O)NC1=O)OC1CCNCC1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21998036 0.85 DDB1 (0.50) DDB1CRBN
SCHEMBL21998083 0.85 DDB1 (0.50) DDB1CRBN
SCHEMBL21998038 0.85 DDB1 (0.50) DDB1CRBN
SCHEMBL23807974 0.82 DDB1 (0.32) DDB1CRBN
SCHEMBL24673887 0.81 SLC6A4 (0.36) DDB1CRBN
SCHEMBL22892879 0.79 DDB1 (0.42) DDB1CRBN
SCHEMBL25162363 0.79 DDB1 (0.38) DDB1CRBN
SCHEMBL26003810 0.78 DDB1 (0.34) DDB1CRBN
SCHEMBL23806947 0.78 DDB1 (0.35) DDB1CRBN
SCHEMBL21106388 0.76 DDB1 (0.32) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885KDM1A 160/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885KDM1A 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.